Associations between donor lymphocyte TL and all-cause and cause-specific mortality after unrelated-donor HCT for SAA
| . | HR (95% CI)*P . | |||
|---|---|---|---|---|
| All-cause mortality . | Infection mortality . | GVHD mortality . | Graft failure mortality . | |
| Total lymphocyte | 0.77 (0.64-0.92) .004 | 0.81 (0.59-1.10) .10 | 1.26 (0.92-1.72) .15 | 0.95 (0.54-1.70) .88 |
| Naïve enriched T cells | 0.81 (0.69-0.95) .009 | 0.84 (0.63-1.14) .26 | 1.20 (0.89-1.61) .23 | 0.82 (0.47-1.43) .49 |
| Memory enriched T cells | 0.77 (0.64-0.93) .008 | 0.72 (0.51-0.97) .06 | 1.11 (0.80-1.55) .52 | 0.95 (0.55-1.63) .84 |
| NK fully differentiated T cells | 0.77 (0.65-0.93) .005 | 0.70 (0.51-0.97) .03 | 1.20 (0.80-1.82) .37 | 0.86 (0.51-1.40) .56 |
| B cells | 0.73 (0.61-0.88) .001 | 0.63 (0.46-0.87) .006 | 1.10 (0.76-1.59) .60 | 1.12 (0.67-1.86) .67 |
| . | HR (95% CI)*P . | |||
|---|---|---|---|---|
| All-cause mortality . | Infection mortality . | GVHD mortality . | Graft failure mortality . | |
| Total lymphocyte | 0.77 (0.64-0.92) .004 | 0.81 (0.59-1.10) .10 | 1.26 (0.92-1.72) .15 | 0.95 (0.54-1.70) .88 |
| Naïve enriched T cells | 0.81 (0.69-0.95) .009 | 0.84 (0.63-1.14) .26 | 1.20 (0.89-1.61) .23 | 0.82 (0.47-1.43) .49 |
| Memory enriched T cells | 0.77 (0.64-0.93) .008 | 0.72 (0.51-0.97) .06 | 1.11 (0.80-1.55) .52 | 0.95 (0.55-1.63) .84 |
| NK fully differentiated T cells | 0.77 (0.65-0.93) .005 | 0.70 (0.51-0.97) .03 | 1.20 (0.80-1.82) .37 | 0.86 (0.51-1.40) .56 |
| B cells | 0.73 (0.61-0.88) .001 | 0.63 (0.46-0.87) .006 | 1.10 (0.76-1.59) .60 | 1.12 (0.67-1.86) .67 |
Regarding HR and 95% CI, models were adjusted for: all cause-mortality: donor age, HLA matching, disease subtype, HCT year, prior SAA therapy, and recipient race; infection-related death: donor age, HLA matching, disease subtype, Karnofsky performance status (KPS), year of HCT, and prior SAA therapy; GVHD-related death: donor age, HLA matching, disease subtype, KPS, year of HCT, prior SAA therapy, and GVHD prophylaxis; and graft failure death: donor age, HLA matching, disease subtype, KPS, year of HCT, and prior SAA therapy.